Item 2.01
Completion of Acquisition or Disposition of Assets.
On May 23, 2018, Spark Therapeutics, Inc. (the Company) closed its previously announced transaction with Jazz Pharmaceuticals Ireland Limited (Jazz) pursuant to which the Company sold its Rare Pediatric Disease Priority Review Voucher (PRV) to Jazz in accordance with the terms of the Asset Purchase Agreement (the Agreement) entered into by the parties on April 30, 2018. The PRV was awarded to the Company by the U.S. Food and Drug Administration in connection with the approval of LUXTURNA (voretigene neparvovec-rzyl), a one-time gene therapy product indicated for the treatment of patients with confirmed biallelic RPE65 mutation-associated retinal dystrophy. In consideration for the PRV, Jazz paid the Company $110,000,000 upon closing of the PRV purchase.
RPE65
mutation-associated retinal dystrophy. In consideration for the PRV, Jazz paid the Company $110,000,000 upon closing of the PRV purchase.
The foregoing description of the Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Agreement. The Company intends to file a copy of the Agreement with the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2018.
